Dermata Therapeutics plans to raise $15 million in its initial public offering of 1.9 million shares at a price range of $7 to $9, Renaissance Capital reported.
Dermata’s lead candidate, DMT310, is a once-weekly topical product currently under clinical development for acne, psoriasis, and rosacea.
The company recently received results from a Phase IIb trial of DMT310 for the treatment of moderate-to-severe acne. It plans to initiate two pivotal Phase III trials in the second half of 2022.










(All Rights Reserved)